Open AccessTherapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm
Author(s) -
Rafat Zrieq,
Najoua Haouas,
Asma M. Khemakhem,
Rawan M. Obeidat,
Reem Ali,
Asma Ayyed AL-Shammary,
Bandar Alsaif,
Fahad D. Algahtani
Publication year - 2020
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2020/v32i2230780
Subject(s) - hydroxychloroquine , medicine , ribavirin , chloroquine , intensive care medicine , covid-19 , medline , pandemic , pneumonia , modalities , lopinavir , pharmacotherapy , disease , virology , immunology , virus , malaria , hepatitis c virus , social science , sociology , political science , infectious disease (medical specialty) , law
Coronavirus disease 2019 (COVID-19) is emerging contagious pneumonia due to the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It initially appeared in Wuhan China in December 2019 then rapidly spread worldwide and became a pandemic. For the time being, there is no specific therapeutic treatment for this disease. Herein, the "state-of-the-art" of treatment modalities was systematically reviewed and ultimately a practical therapeutic algorithm for the COVID-19 management was proposed. The systematic review was performed by using published articles retrieved from Science Direct, MEDLINE, and Scopus databases concerning this topic. Among 1060 articles collected from the different databases, 19 publications were studied in-depth and incorporated in this review. The most three frequently used medications for the treatment of COVID-19 was: the available anti-viral drugs (n= 9), the antimalarial hydroxychloroquine or chloroquine (n = 8), and the passive antibody transfer therapy (n = 2). Among all treatment modalities, antimalarial hydroxychloroquine ranked the highest cure rate. Therefore, this drug is considered as the first‐line of COVID-19 treatment. The second‐line treatment includes the lopinavir/ritonavir drugs combined with interferon β-1b and ribavirin. Finally, the third‐line treatments include the remdesivir drug and passive antibody transfer therapy. However, our review emphasis the urgent need for adequately designed randomized controlled trials, enabling a more significant comparison between the most used treatment modalities.